## AMENDMENT TO THE CLAIMS

Please cancel claims 3 and 4.

Please enter rewritten claims 1, 2, 5 and 6 as provided below.

1. (Currently Amended) A method for the treatment of migraine ~~disorders responsive to opening of the KCNQ potassium channels~~ in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I



I

wherein

$R^1$ is selected from hydrogen, halogen, $C_{1-8}$alkyl, phenyl, phenylalkyl, $C_{3-6}$heterocyclic, $C_{3-6}$heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or $-CF_3$;

$R^2$ is selected from halogen, $C_{1-8}$alkyl, $C_{3-7}$cycloalkyl, phenyl, phenylalkyl, $C_{3-6}$heterocyclic, $C_{3-6}$heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or -S-R;

$R^3$ is selected from hydrogen, halogen or $C_{1-8}$alkyl;

$R^4$ is selected from hydrogen, $-CH_3$ or $-CH_2C_6H_5$;

$R^5$ is selected from hydrogen, $C_{1-8}$alkyl, $C_{3-7}$cycloalkyl, phenyl, phenylalkyl, $C_{3-6}$heterocyclic or $C_{3-6}$heterocyclicmethyl;

wherein each occurrence of R is independently selected from the group consisting of $C_{1-8}$alkyl, $C_{3-7}$alkynyl, phenyl, phenylalkyl, $C_{3-6}$heterocyclic and $C_{3-6}$heterocyclicmethyl.

2. (Currently Amended) ~~The of claim 1 wherein the compound of Formula I is selected from a compound having the structure~~ A method for the treatment of migraine in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I



wherein

$R^1$ is hydrogen;

$R^2$ is selected from the group consisting of $NR^6R^7$, $SR^8$, $OR^9$, phenyl, and thienyl; in which said phenyl is optionally substituted with one or two $C_{1-3}$alkoxy groups;

$R^3$ is selected from the group consisting of $C_{1-6}$alkyl, trifluoromethyl, $C_{3-7}$cycloalkyl, $C_{3-7}$cycloalkylmethyl, phenyl, amino, di($C_{1-3}$alkyl)amino and pyrrolidinyl; in which said phenyl is optionally substituted with a halogen;

$R^4$ is selected from the group consisting of phenylmethyl, furanylmethyl, and $C_{3-7}$cycloalkylmethyl; in which the phenyl of said phenylmethyl is optionally substituted with one substituent selected from the group consisting of halogen, $C_{1-3}$alkyl, di($C_{1-3}$alkyl)amino, trifluoromethyl, trifluoromethoxy, and trifluoromethylthio; and in which the furanyl of said furanylmethyl is optionally substituted with a $C_{1-3}$alkyl group;

$R^5$ is hydrogen;

$R^6$ and $R^7$ are each independently selected from the group consisting of hydrogen, $C_{1-6}$alkyl, $C_{3-7}$cycloalkyl, $C_{3-7}$alkynyl, phenyl, and phenylmethyl; in which said $C_{1-6}$alkyl is optionally substituted with a hydroxy group and in which said phenyl is optionally substituted with one or two substituents selected from the group consisting of halogen, trifluoromethoxy, and nitro; or $R^6$ and $R^7$ taken together with the nitrogen to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidinyl, morpholinyl, piperidinyl, homopiperidinyl, methylpiperidinyl, and 1,2,3,4-tetrahydoisoquinolinyl;

$R^8$ is selected from the group consisting of $C_{1-6}$alkyl, $C_{3-7}$cycloalkyl, phenyl, phenylmethyl, furanylmethyl, and thienyl; in which said phenyl is optionally

substituted with one halogen or nitro group; and wherein the phenyl of said phenylmethyl is optionally substituted with one halogen or $C_{1-3}$alkyl group; and

$R^9$ is selected from the group consisting of $C_{3-7}$alkynyl, phenyl, 1-(4-fluorophenyl)ethyl, and thienylmethyl; in which said phenyl is optionally substituted with a halogen or $C_{1-3}$alkoxy group.

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition for the treatment of migraine ~~disorders responsive to opening of KCNQ potassium channels~~ comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.

6. (Currently Amended) A pharmaceutical composition for the treatment of migraine ~~disorders responsive to opening of KCNQ potassium channels~~ comprising a therapeutically effective amount of the compound of claim 2 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.